Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹56.60down ₹1.33 (2.30%)BSE ₹58.36
Share price at the NSE close on 30 Oct 2026. Previous close ₹57.93.
30 Oct: open ₹56.60, high ₹58.49, low ₹56.33
52-week range of traded prices to 30 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹122 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,39760.1% delivered
Krebs Biochemicals and Industries share news and announcements
498 announcements, routine notices left out, newest first. Page 8 of 10.
Nov 2015
Oct 2015
8 Oct · Meeting
Sep 2015
Aug 2015
Jun 2015
May 2015
25 May · Code of Conduct under SEBI(PIT) Reg., 2015
11 May · Board meeting
Apr 2015
Mar 2015
Feb 2015
14 Feb · Public Announcement-Open Offer
13 Feb · Board meeting
6 Feb · Board meeting
To consider inter alia the following: 1. Un-Audited Financial results for the First Quarter ended December 31, 2014. 2. Any other matter with the permission of the Chair.
Jan 2015
7 Jan · Board meeting
Krebs Biochemicals Limited had informed the Exchange regarding the outcome of the Board meeting though their letter dated December 13, 2014. The Company has now informed the Exchange that due to a clerical error in point No.2 (a) Increase in authorised Share capital of the company from Rs 10.00 Crores to Rs 16.00 Crores which may please be rectified as (a) increase in authorised Share capital of the company from Rs.10.00 Crores To Rs.20.00 Crores.
Dec 2014
15 Dec · Board meeting
At the Board meeting of the Company held on December 13, 2014 following business were duly considered: (1) The Board approved the resignation of Sri. R.Ch. Satyanarayana as Director w.e.f. December 3, 2014 who resigned due to his personal reasons. (2). The Board has decided to a) increase the Authorised Share Capital of the company from Rs.10.00 Crores to Rs.16.00 Crores. b) to amend the Memorandum of Association and Articles of Association of the company accordingly . It has been decided to seek the approval of the members by way of postal ballot. Mrs. K.Jhansi Laxmi, practicing Company Secretary, Hyderabad was appointed as the scrutiniser for conducting the postal ballot process in a fair and transparent manner.
Nov 2014
20 Nov · Board meeting
To consider inter alia the following: 1. Audited Financial results for the Fifteen months period from July 1, 2013 to September 30, 2014. 2. To consider and approve the draft auditors report for the period from July 1, 2013 to September 30, 2014. 3. To consider and recommend the draft Directors Report for the period from July 1, 2013 to September 30, 2014 along With the draft Notice for the Annual General Meeting of the Company. 4. Any other matter with the permission of the Chair.
Sep 2014
23 Sep · Board meeting
To consider the following : 1. To take note of the scrutiniser's Report on Postal Ballot and declaring the results.
Aug 2014
20 Aug · Management
Following changes have taken place in directorship of the company. 1. P. Nagaraju (Nominee Director of IDBI Bank) - Resigned w.e.f. May 22, 2014. 2. R. Ch Satyanarayana (Small Shareholders Director) - Resigned w.e.f. February 17, 2014. 3. Daya Chandrahas (Nominee Director of Exim Bank) - Resigned w.e.f. December 31, 2013.6 Aug · Board meeting
To consider the following: 1. Unaudited financial results for the quarter ended June 30, 2014 and the Unaudited financial results for the twelve months period from July 01, 2013 to June 30, 2014. 2. Any other matter with the permission of the Chair.